Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;15(4):e200488.
doi: 10.1212/CPJ.0000000000200488. Epub 2025 Jul 17.

Neuroimaging Findings of CAR T-Cell-Associated Neurotoxicity: A Review

Affiliations
Review

Neuroimaging Findings of CAR T-Cell-Associated Neurotoxicity: A Review

Aditi Vichare et al. Neurol Clin Pract. 2025 Aug.

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has remarkable efficacy in treating refractory hematologic malignancies. However, CAR-T therapy may induce neurotoxic effects in some patients. Common symptoms of neurotoxicity range from early signs such as headache, confusion, delirium, and aphasia to severe manifestations such as seizures, motor weakness, increased intracranial pressure, cerebral edema, and coma. Magnetic resonance imaging (MRI) can offer invaluable insight into resulting abnormalities in the structure, physiology, and function of the central nervous system. This review aims to examine the current literature on brain MRI findings of CAR-T-induced neurotoxicity, elucidating its diagnostic capabilities, clinical implications, and emerging trends in advancing imaging modalities. An improved understanding of neural correlates of CAR-T neurotoxicity is important for early detection, development of neuroprotective strategies, and optimization of CAR-T regimens to maximize therapeutic efficacy while minimizing adverse neurotoxic effects.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

References

    1. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-398. doi: 10.1158/2159-8290.cd-12-0548 - DOI - PMC - PubMed
    1. Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: what is next? Cancers (Basel). 2023;15(3):663. doi: 10.3390/cancers15030663 - DOI - PMC - PubMed
    1. Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020;20(6):653-664. doi: 10.1080/14712598.2020.1729735 - DOI - PMC - PubMed
    1. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2021;39(35):3978-3992. doi: 10.1200/JCO.21.01992 - DOI - PubMed
    1. Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs. 2018;32(12):1091-1101. doi: 10.1007/s40263-018-0582-9 - DOI - PMC - PubMed

LinkOut - more resources